AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23642378 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 241
Study 23642378 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 241
Study 21249462 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive plan (Deposit contracts, matched 1:1)
Number of subjects: 0
Study 21249462 — intervention group
Group type: COMPARATOR
Intervention: Weight-monitoring program (control condition)
Number of subjects: 0
Study 19380447 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 2122
Study 19380447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2122
Study 17578484 — intervention group
Group type: COMPARATOR
Intervention: 300 microg capsaicin
Number of subjects: 12
Study 17578484 — intervention group
Group type: COMPARATOR
Intervention: 1000 microg capsaicin
Number of subjects: 12
Study 17578484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15223721 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer drugs (ACE inhibitors, calcium antagonists)
Number of subjects: 2280
Study 15223721 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (diuretics, beta-blockers)
Number of subjects: 2280
Study 11816637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combipolar sensing configuration
Number of subjects: 26
Study 11816637 — intervention group
Group type: COMPARATOR
Intervention: Unipolar sensing
Number of subjects: 26
Study 11816637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combipolar sensing
Number of subjects: 26
Study 9161624 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg i.v. over 5 minutes
Number of subjects: 13
Study 9161624 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 micrograms/kg i.v. over 30 seconds
Number of subjects: 13
Study 9161624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 32 mg i.v. over 15 minutes
Number of subjects: 13
Study 9161624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8125423 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 8125423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3508564 — intervention group
Group type: EXPERIMENTAL
Intervention: Three production lots of macrocrystalline nitrofurantoin capsules (Macrodantin)
Number of subjects: 21
Study 3508564 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules from one production lot administered on three occasions
Number of subjects: 21
Study 3508564 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 21
Study 2744361 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the esophagus at 37 cm
Number of subjects: 11
Study 2744361 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the esophagus at 0.5 and 1.0 Hz
Number of subjects: 11
Study 2744361 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation at 37 cm
Number of subjects: 11
Study 2744361 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular stimulation and stimulation during mental distraction
Number of subjects: 11
Study 31520099 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exertion (PE) - combined isometric modified Biering‐Sörensen and static abdominal curl
Number of subjects: 20
Study 31520099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive exertion (CE) - modified incongruent Stroop colour‐word task
Number of subjects: 20
Study 31520099 — intervention group
Group type: COMPARATOR
Intervention: Seated rest without exertion (NE)
Number of subjects: 20
Study 26892006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin plus paroxetine
Number of subjects: 75
Study 26892006 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin plus amitriptyline
Number of subjects: 75
Study 26892006 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin plus venlafaxine
Number of subjects: 75
Study 25992866 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cold patch
Number of subjects: 40
Study 25992866 — intervention group
Group type: COMPARATOR
Intervention: Wash group (ice-cold balanced salt solution)
Number of subjects: 40
Study 22616762 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (doses ranging from 0.03 to 3.0 g)
Number of subjects: 0
Study 22303708 — intervention group
Group type: COMPARATOR
Intervention: Probucol Tablet (PT) 0.5 g, twice daily
Number of subjects: 150
Study 22303708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbrukinase Capsule (LC) 600 thousand U, thrice daily + Probucol Tablet (PT)
Number of subjects: 150
Study 19335806 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and knowledge assessment of lifeguards regarding anaphylaxis management
Number of subjects: 50
Study 19335806 — intervention group
Group type: EXPERIMENTAL
Intervention: Possession of emergency kits for anaphylaxis management
Number of subjects: 50
Study 16707027 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine completion and feedback of outcome measures (FOCUS intervention)
Number of subjects: 160
Study 14982689 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg nicotine
Number of subjects: 24
Study 14982689 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg nicotine
Number of subjects: 24
Study 14982689 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine
Number of subjects: 24
Study 14982689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14982689 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dosing with The Straw
Number of subjects: 24
Study 11502768 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I plus pretreatment with methimazole (30 mg/d)
Number of subjects: 61
Study 11502768 — intervention group
Group type: COMPARATOR
Intervention: 131I alone
Number of subjects: 61
Study 9248982 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative changes in serum concentrations of IL-2 after major operations
Number of subjects: 43
Study 9248982 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative changes in serum concentrations of IL-2 after intermediate operations
Number of subjects: 43
Study 9248982 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative changes in serum concentrations of IL-2 after minor operations
Number of subjects: 43
Study 9248982 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antiprostaglandins and H2-blockers
Number of subjects: 43
Study 9248982 — intervention group
Group type: COMPARATOR
Intervention: Healthy age and sex matched controls
Number of subjects: 43
Study 8215594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant odor
Number of subjects: 0
Study 8215594 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant odor
Number of subjects: 0
Study 8215594 — intervention group
Group type: EXPERIMENTAL
Intervention: No odor
Number of subjects: 0
Study 3544982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 10 mg
Number of subjects: 94
Study 3544982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 10 mg plus Hydroxyzine 50 mg
Number of subjects: 94
Study 3544982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg
Number of subjects: 94
Study 3544982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 30428134 — intervention group
Group type: EXPERIMENTAL
Intervention: Taoist qigong training program for one month
Number of subjects: 43
Study 30428134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 28399810 — intervention group
Group type: COMPARATOR
Intervention: Implementation of an off-line database that integrates laboratory results and generates eGFR graphs over time.
Number of subjects: 0
Study 28399810 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of eGFR graph surveillance intervention.
Number of subjects: 0
Study 24838062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy and BSS-BSSG mixture (20 mg sterol and 0.2 mg sterolin)
Number of subjects: 123
Study 24838062 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy only
Number of subjects: 123
Study 23439415 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 19
Study 23439415 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity activity breaks
Number of subjects: 19
Study 23439415 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity activity breaks
Number of subjects: 19
Study 23439415 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity and moderate-intensity breaks
Number of subjects: 19
Study 23439415 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity breaks
Number of subjects: 19
Study 21086166 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg bid for 1 week
Number of subjects: 70
Study 21086166 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PPIs)
Number of subjects: 70
Study 18300257 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD plus bortezomib
Number of subjects: 646
Study 18300257 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 646
Study 16937744 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-3 group, 1 drop 3 times daily for 2 years
Number of subjects: 64
Study 16937744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-3 group, 1 drop twice daily in year 1 and 1 drop 3 times daily in year 2
Number of subjects: 64
Study 16937744 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-3 group, 1 drop once daily in year 1 and 1 drop 3 times daily in year 2
Number of subjects: 64
Study 16937744 — intervention group
Group type: COMPARATOR
Intervention: Control group, no treatment
Number of subjects: 64
Study 14604245 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 field flooding
Number of subjects: 18
Study 14604245 — intervention group
Group type: COMPARATOR
Intervention: Mechanical de-airing
Number of subjects: 18
Study 10609721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound at first visit
Number of subjects: 648
Study 10609721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound assessment)
Number of subjects: 648
Study 7492863 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5-25 mg/day)
Number of subjects: 113
Study 7492863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 2020772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 15
Study 2020772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen breathing
Number of subjects: 15
Study 6803944 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2-2.5 mg/kg body weight over six months)
Number of subjects: 44
Study 6803944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 28407148 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD-CLS pacing (60-130/min)
Number of subjects: 30
Study 28407148 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing (60/min)
Number of subjects: 30
Study 26692347 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCB
Number of subjects: 131
Study 26692347 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCB processing speed and attention
Number of subjects: 131
Study 26692347 — intervention group
Group type: COMPARATOR
Intervention: Participants in 'low complexity' work category
Number of subjects: 131
Study 26692347 — intervention group
Group type: COMPARATOR
Intervention: Participants working sheltered jobs
Number of subjects: 131
Study 25069770 — intervention group
Group type: EXPERIMENTAL
Intervention: Milbemax® (milbemycin oxime/praziquantel) at a minimum target dose of 0.5 mg/kg bodyweight and 5 mg/kg bodyweight respectively, administered once every 4 weeks.
Number of subjects: 249
Study 25069770 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (T2) receiving specific parasiticide treatments when necessary.
Number of subjects: 249
Study 22705017 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-prescribed Chinese herbal medicine (CHM)
Number of subjects: 424
Study 22705017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CKD)
Number of subjects: 424
Study 22705017 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional use of non-prescribed CHM
Number of subjects: 424
Study 22705017 — intervention group
Group type: EXPERIMENTAL
Intervention: Illiteracy
Number of subjects: 424
Study 22705017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 424
Study 22705017 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 424
Study 20634975 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 24
Study 20634975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18382796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms with midazolam 1 mg IV
Number of subjects: 100
Study 18382796 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3 microgram/kg with midazolam 1 mg IV
Number of subjects: 100
Study 15755572 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV plasmid vaccine (combination of two HIV DNA plasmid constructs)
Number of subjects: 13
Study 15755572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15755572 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV plasmid vaccine
Number of subjects: 13
Study 12093983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream
Number of subjects: 713
Study 12093983 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (emollients and topical corticosteroids)
Number of subjects: 713
Study 9585803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemisinin (500 mg daily)
Number of subjects: 30
Study 9585803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artemisinin (500 mg daily)
Number of subjects: 30
Study 9585803 — intervention group
Group type: COMPARATOR
Intervention: Rectal artemisinin
Number of subjects: 30
Study 9585803 — intervention group
Group type: COMPARATOR
Intervention: Oral artemisinin
Number of subjects: 30
Study 9585803 — intervention group
Group type: COMPARATOR
Intervention: Oral treatment
Number of subjects: 30
Study 8583211 — intervention group
Group type: COMPARATOR
Intervention: HAM/TSP
Number of subjects: 149
Study 8583211 — intervention group
Group type: COMPARATOR
Intervention: PPMS
Number of subjects: 149
Study 8583211 — intervention group
Group type: COMPARATOR
Intervention: RRMS
Number of subjects: 149
Study 2489552 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Tetracycline (TC) strips
Number of subjects: 46
Study 2489552 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips
Number of subjects: 46
Study 69828 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg/day, 3 days/week)
Number of subjects: 37
Study 69828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 69828 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 37
Study 31618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic drainage by the same intercostal space of thoracotomy
Number of subjects: 40
Study 31618286 — intervention group
Group type: COMPARATOR
Intervention: Traditional chest drainage approach
Number of subjects: 40
Study 31618286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 29790612 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 MHz, invasive, bipolar RF treatment with longer conduction time and lower power (LC/LP)
Number of subjects: 2
Study 29790612 — intervention group
Group type: COMPARATOR
Intervention: 0.5 MHz, invasive, bipolar RF treatment with shorter conduction time and higher power (SC/HP)
Number of subjects: 2
Study 29023508 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV)
Number of subjects: 90
Study 29023508 — intervention group
Group type: COMPARATOR
Intervention: Control (non-ATV containing regimens)
Number of subjects: 90
Study 26035431 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 6502
Study 26035431 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 6502
Study 26035431 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 6502
Study 23678153 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 444
Study 23678153 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 444
Study 23678153 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 444
Study 23678153 — intervention group
Group type: COMPARATOR
Intervention: delayed golimumab treatment (Group 1)
Number of subjects: 444
Study 23678153 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + placebo
Number of subjects: 444
Study 21749629 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led unit
Number of subjects: 1111
Study 21749629 — intervention group
Group type: COMPARATOR
Intervention: Normal unit
Number of subjects: 1111
Study 21749629 — intervention group
Group type: COMPARATOR
Intervention: Special unit
Number of subjects: 1111
Study 19818690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ascorbic acid per day
Number of subjects: 179
Study 19818690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g ascorbic acid per day
Number of subjects: 179
Study 19818690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 18039724 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized interactive decision aid
Number of subjects: 149
Study 15969264 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 meals replacement a day plus nutritional and physical orientation for 3 months followed by 1 meal replacement for 3 months
Number of subjects: 78
Study 15969264 — intervention group
Group type: COMPARATOR
Intervention: 1 meal replacement for 3 months followed by 1 meal replacement for 3 months (control group)
Number of subjects: 78
Study 11336869 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone diary
Number of subjects: 105
Study 11336869 — intervention group
Group type: COMPARATOR
Intervention: Written diary
Number of subjects: 105
Study 11336869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diary modes
Number of subjects: 105
Study 11336869 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher risk teens
Number of subjects: 105
Study 9145445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (2 x 10 g/d)
Number of subjects: 36
Study 9145445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol (2 x 10 g/d)
Number of subjects: 36
Study 9145445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7787594 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 86
Study 7787594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 2122422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feedings (Ensure)
Number of subjects: 6
Study 2122422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of aminophylline
Number of subjects: 6
Study 2122422 — intervention group
Group type: COMPARATOR
Intervention: Phase 1 (Theo-24 6 mg/kg with 100 ml of water)
Number of subjects: 6
Study 2122422 — intervention group
Group type: COMPARATOR
Intervention: Phase 2 (Enteral feedings with Theo-24)
Number of subjects: 6
Study 690225 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems Releasing Action Therapy (SRAT)
Number of subjects: 56
Study 690225 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 31418966 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week home-based isometric handgrip training at 30% of maximal voluntary isometric contraction
Number of subjects: 40
Study 31418966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 29718188 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning labels (GWLs) with high emotional reaction (ER) images
Number of subjects: 73
Study 29718188 — intervention group
Group type: COMPARATOR
Intervention: Graphic warning labels (GWLs) with low emotional reaction (ER) images
Number of subjects: 73
Study 29306232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 100 μg per day
Number of subjects: 120
Study 29306232 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4/5 mg per day
Number of subjects: 120
Study 29306232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate + Montelukast
Number of subjects: 120
Study 29306232 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 120
Study 24823842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics intervention (nurse counseling, brochure, DVD, manual, pharmaceuticals, 1‐800‐QUIT‐NOW card, post‐discharge telephone calls)
Number of subjects: 1070
Study 24823842 — intervention group
Group type: COMPARATOR
Intervention: Control site (Indianapolis)
Number of subjects: 1070
Study 22473435 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (n = 443)
Number of subjects: 952
Study 22473435 — intervention group
Group type: COMPARATOR
Intervention: Usual Bureau of Motor Vehicles license practices (control; n = 509)
Number of subjects: 952
Study 20558967 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training conducted twice a week for 12 weeks.
Number of subjects: 119
Study 20558967 — intervention group
Group type: COMPARATOR
Intervention: Health education classes (control group).
Number of subjects: 119
Study 18182669 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced induction therapy (no anthracyclines) for SR patients
Number of subjects: 1744
Study 18182669 — intervention group
Group type: COMPARATOR
Intervention: Vincristine and dexamethasone pulses during maintenance for IR patients
Number of subjects: 1744
Study 18182669 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional BFM schedule intensified with three chemotherapy blocks followed by a double reinduction phase for HR patients
Number of subjects: 1744
Study 18182669 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable DNA index in IR patients
Number of subjects: 1744